How to keep the weight off after a GLP-1: what each trial tested

Reviewed 12 sourcesPublished by PepVault

What each trial tested for keeping weight off after a GLP-1: staying on, a lower dose, switching to a pill and exercise, with every result in one by-drug table.

Four glass meal-prep boxes of salmon, broccoli, rice and peppers on marble, with lemons and parsley
Last reviewed
Sources
12
Questions
7
Compounds
4

The short answer

Staying on the drug kept the weight off best. In SURMOUNT-MAINTAIN, people who stayed on their top tirzepatide dose ended 112 weeks 21.9% below their starting weight, those cut to 5 mg 16.6% and those switched to placebo 9.9%. Moving from the shot to the orforglipron pill kept three-quarters of the loss or more. A year of supervised exercise still held a year after it ended.

Every number checked at its primary source · · 12 sources · How we research

Evidence: Randomised, double-blind trials in people (STEP 4, SURMOUNT-4, SURMOUNT-MAINTAIN, ATTAIN-MAINTAIN and the Lundgren exercise trial with its one-year follow-up), the STEP 1 off-treatment extension, and the FDA labels for Wegovy, Zepbound and Foundayo; the four drug-company trials were funded by the drug's maker.

Four glass meal-prep boxes of salmon, broccoli, rice and peppers on marble, with lemons and parsley

Which ways of keeping the weight off have trials tested?

Trials have now tested five strategies: stopping (a switch to placebo, a dummy shot or pill with no drug in it), staying on the drug, dropping to a lower dose, switching from the shot to a pill, and exercise. Each trial first let people lose weight, then split them at random into groups and followed them for about a year13457.

StrategyTrial and drugDown at the splitWhat happened over the next year
Stop everythingSTEP 1 extension, semaglutide 2.4 mg, with the diet and activity programme stopped too17.3% at week 6811.6 points of the starting weight regained by week 120, about two-thirds of the loss; 5.6% below the start6
Stop (switch to placebo)STEP 4, semaglutide 2.4 mg10.6% at week 20Up 6.9% from the weight at the switch over 48 weeks5
Stop (switch to placebo)SURMOUNT-4, tirzepatide 10 or 15 mg20.9% at week 36Up 14.0% from the weight at the switch over 52 weeks; 16.6% kept at least 80% of their loss4
Stay on the drugSTEP 4, semaglutide 2.4 mg10.6% at week 20A further 7.9% lost over 48 weeks5
Stay on the drugSURMOUNT-4, tirzepatide 10 or 15 mg20.9% at week 36A further 5.5% lost; 89.5% kept at least 80% of their loss; 25.3% below the start at week 884
Stay on the top doseSURMOUNT-MAINTAIN, tirzepatide 10 or 15 mgAfter 60 weeks on the top doseAll of the loss kept on average in Lilly's on-treatment analysis; 21.9% below the start at week 112 in the paper's main analysis12
Lower doseSURMOUNT-MAINTAIN, tirzepatide cut to 5 mgAfter 60 weeks on the top doseAll but 5.6 kg of the loss kept in Lilly's on-treatment analysis; 16.6% below the start at week 112 in the paper's main analysis, against 9.9% on placebo12
Shot to pillATTAIN-MAINTAIN, tirzepatide shot to orforglipron21.5% at the switch16.8% below the start a year later; 74.7% of the loss kept by those whose weight had levelled off before the switch, against 49.2% on placebo3
Shot to pillATTAIN-MAINTAIN, semaglutide shot to orforglipron16.5% at the switch15.1% below the start a year later; 79.3% of the loss kept by those whose weight had levelled off, against 37.6% on placebo3
ExerciseLundgren trial, supervised exercise with or without liraglutide 3.0 mg, after an 8-week diet13.1 kg at the splitExercise plus liraglutide kept off 9.5 kg more than placebo over the year; exercise alone held its weight a year after the programme ended78

Each trial counts from its own starting point, so the percentages compare groups inside one trial best, not one trial with another. And from about six months in, SURMOUNT-MAINTAIN and ATTAIN-MAINTAIN offered the drug back to anyone who regained about half of their loss or more, so their placebo groups are not a clean stop13.

PepVault's weight log draws a smoothed trend under your weigh-ins, and once you reach your goal it counts the days the trend has held within reach of it: what these trials were measuring. Track your weight in PepVault

A smiling woman in a blue top leaning on her kitchen counter with her phone and a notebook

PepVault for iPhone

Keep your protocol in PepVault

PepVault's weight log draws a smoothed trend under your weigh-ins, and once you reach your goal it counts the days the trend has held within reach of it: what these trials were measuring.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Does staying on the drug keep the weight off?

Yes, in every trial that tested it. In STEP 4, people who stayed on semaglutide 2.4 mg kept losing for another 48 weeks while the placebo group regained5. In SURMOUNT-4, nine in ten of those who stayed on tirzepatide kept at least 80% of what they had lost, against one in six on placebo4. SURMOUNT-MAINTAIN ran the longest, 112 weeks in all, and those who stayed on their top tolerated dose of tirzepatide (the highest they could take comfortably, 10 or 15 mg) ended 21.9% below where they started1.

The labels are written for this. Wegovy, Zepbound and the Foundayo pill are each approved to reduce excess body weight and to maintain that reduction long term, and none of the three sets an end date91011. The SURMOUNT-MAINTAIN authors say long-term treatment is often needed to keep the weight off1.

Does a lower maintenance dose keep the weight off?

Mostly, for tirzepatide. SURMOUNT-MAINTAIN is the one published trial that tested a step down: after 60 weeks on 10 or 15 mg, one group was cut to 5 mg for a year. In the paper's main analysis they ended 16.6% below their starting weight, against 21.9% on the top dose and 9.9% on placebo1. Lilly's on-treatment analysis has them keeping all but 5.6 kg of their loss2. A quarter of the 5 mg group regained more than half of their loss and took rescue tirzepatide, against 8% on the top dose and 67% on placebo1. The authors call 5 mg a possible alternative to stopping and add that responses vary from person to person1.

The labels allow lower maintenance doses, the steady dose a treatment settles on after the dose climb. Zepbound's lists 5, 10 or 15 mg once weekly for weight reduction and long-term maintenance, chosen by response and tolerability9. Wegovy's injection label lists 1.7 mg or 2.4 mg for adults, with 2.4 mg recommended, and allows a step up to 7.2 mg when more loss is needed10. We found no published trial of a lower semaglutide maintenance dose after weight loss. A trial comparing a 16-week step-down of semaglutide with an abrupt stop, in people treated for weight regain after weight-loss surgery, is registered by an Egyptian teaching-hospital group; its record still reads not yet recruiting12. Which dose fits is the prescriber's decision.

Can you switch from a GLP-1 shot to a pill and keep the weight off?

ATTAIN-MAINTAIN tested exactly that. It took 376 people who had just finished SURMOUNT-5, a trial of the tirzepatide and semaglutide shots, and moved them straight to daily orforglipron (sold as Foundayo) or to a placebo pill for a year3. Those who came from semaglutide held almost everything: 16.5% below their starting weight at the switch, 15.1% a year later. Those who came from tirzepatide gave back about five percentage points: 21.5% at the switch, 16.8% a year later3.

The move itself went smoothly. People started on a 12 mg capsule (the trial's capsule, equal to the 9 mg Foundayo tablet), a middle step of the pill's dose climb, instead of the lowest dose, and no one needed a lower dose in the first four weeks3. The trial had no group that stayed on the injection, so it cannot say whether the pill holds weight as well as the shot it replaced3. Foundayo's label carries the maintenance indication but gives no rule for moving over from an injection11.

Does exercise help keep the weight off after a GLP-1?

It is the one strategy whose effect outlasted the treatment. In the Lundgren trial in Copenhagen, 195 adults first lost 13.1 kg on an 8-week low-calorie diet, then spent a year on supervised exercise, daily liraglutide 3.0 mg (an older, daily GLP-1 shot), both, or neither7. Over that year, both together kept off the most, 9.5 kg more than placebo, with about twice the drop in body-fat percentage of either one alone7.

Then the treatment stopped, and the researchers weighed people again a year later. The exercise group had kept its weight and body composition. The liraglutide-only group regained 6.0 kg more than the exercise group over that year, and the combination group ended 5.1 kg lighter than the liraglutide-only group, counted from the start of the year of treatment8. A year on, the former exercisers still reported a median of 240 minutes a week of moderate to vigorous activity, against 30 minutes for those who had taken liraglutide alone8. The trial used liraglutide, not semaglutide or tirzepatide, and we found no published trial that has run the same test with the newer shots.

Commonly reported: hunger coming back over a few weeks after the last shot rather than overnight; people settling on a lower dose with their prescriber and holding steady; and others spacing doses further apart, a pattern no trial here has tested.

What did the people who kept the weight off do in the trials?

What the trials had people do, in order, told as what was studied, not as a plan for anyone:

  1. Lost the weight first on the drug's full dose climb: 20 weeks in STEP 4, 36 in SURMOUNT-4 and 60 in SURMOUNT-MAINTAIN145.
  2. Stayed on the drug once the weight had dropped: semaglutide 2.4 mg weekly in STEP 4, tirzepatide 10 or 15 mg weekly in SURMOUNT-4, or 5 mg weekly in SURMOUNT-MAINTAIN's lower-dose group145.
  3. Or moved from the shot to a daily orforglipron pill, starting at the 12 mg capsule (equal to the 9 mg tablet) and climbing to the top tolerated dose, in ATTAIN-MAINTAIN3.
  4. Kept lifestyle counselling on healthy eating and physical activity going the whole time, as every group in STEP 4, SURMOUNT-4 and ATTAIN-MAINTAIN did345.
  5. In the exercise trial, built up over six weeks, then were asked to do two supervised group sessions a week of hard indoor cycling and circuit training plus two sessions of moderate to vigorous exercise on their own, for a year8.
  6. Were weighed through the year, so a regain showed early: the two newest trials offered the drug back to anyone who had regained about half of their loss or more13.

If your plan is to stay on a weekly shot, PepVault can remind you around the dose time you set for each compound, so the maintenance dose lands on its day. Set reminders in PepVault

How many in the placebo groups needed the drug back?

Most of them, in the two newest trials. In ATTAIN-MAINTAIN, only 31.3% of the placebo group that came from tirzepatide, and 18.2% of the group that came from semaglutide, got through the 52 weeks without rescue treatment or another weight medicine3. In SURMOUNT-MAINTAIN, two-thirds of the placebo group regained more than half of their loss and took rescue tirzepatide1. The regain after a stop, week by week and drug by drug, is in our guide on stopping a GLP-1.

These are trial averages and the labels' doses, not a plan for continuing, lowering, switching or stopping any one person's treatment; that decision is made with the prescriber.

Track it in the app

Sources

  1. Horn DB et al. Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2026. PubMed 42119587
  2. Eli Lilly and Company. Lilly's Foundayo and lower-dose Zepbound helped people maintain weight loss after switching from higher doses of injectable incretin therapy in two late-phase trials. Press release, May 12, 2026. investor.lilly.com
  3. Aronne LJ et al. Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial. Nat Med. 2026. PubMed 42120723
  4. Aronne LJ et al.; SURMOUNT-4 Investigators. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024. PubMed 38078870
  5. Rubino D et al.; STEP 4 Investigators. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021. PubMed 33755728
  6. Wilding JPH et al.; STEP 1 Study Group. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022. PubMed 35441470
  7. Lundgren JR et al. Healthy weight loss maintenance with exercise, liraglutide, or both combined. N Engl J Med. 2021. PubMed 33951361
  8. Jensen SBK et al. Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial. EClinicalMedicine. 2024. PubMed 38544798
  9. Eli Lilly and Company. ZEPBOUND (tirzepatide) injection, prescribing information. DailyMed, revised August 2026. dailymed.nlm.nih.gov
  10. Novo Nordisk. WEGOVY (semaglutide) injection and tablets, prescribing information. DailyMed, revised June 2026. dailymed.nlm.nih.gov
  11. Eli Lilly and Company. FOUNDAYO (orforglipron) tablets, prescribing information. DailyMed, August 2026. dailymed.nlm.nih.gov
  12. ClinicalTrials.gov NCT07859176. Tapered versus abrupt discontinuation of semaglutide after treatment of recurrent weight gain or suboptimal response following metabolic and bariatric surgery (sponsor General Committee of Teaching Hospitals and Institutes, Egypt). Not yet recruiting (record last updated October 2026). clinicaltrials.gov

Newsletter · Weekly

The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

We’ll email you a link to confirm. Your address is used for the briefing only. Privacy

PepVault for iPhone

Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo